Magnetic Resonance Imaging in Obesity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

49 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-05-31

Study Completion Date

2021-12-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obesity and its related conditions account for up to 5%of all health care spending in the UK and this is expected to double by 2030. Following weight loss, significant improvement in these obesity-related illnesses has been reported. However, there is limited understanding of how these improvements happen and in particular, little dedicated work has been done using imaging in the obese population to look at the effects of treatment.

Magnetic resonance imaging (MRI) is an imaging technique that allows assessment of fat concentration and volume without the use of ionising radiation. It is safe, non-invasive and well-tolerated by most patients.

There are several MRI imaging techniques that be can used for fat quantification. These include MR spectroscopy and Dixon methods with measurement of fat fraction. These techniques measure the fat in the body organs and also the fat in the abdomen and skin. Recent technical developments mean that the whole body can be scanned relatively quickly (typically 30-40 minutes).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Weight Loss Surgery in Adolescents With NAFLD

NCT02952170

NAFLD Obesity, Adolescent

COMPLETED NA

Clinical Classification and Imaging Markers in Patients of Obesity

NCT06649071

Obesity fMRI Clinical Classification

ENROLLING_BY_INVITATION

Anthropometric Assessment of Abdominal Obesity and Health Risk in Children and Adolescents

NCT01595100

Obesity

COMPLETED

Exploring Liver and Muscle Fat Content Using MRI

NCT05592080

Polycystic Ovary Syndrome

COMPLETED

The Effect of Obesity and Weight Loss in Heart Failure With Preserved Ejection Fraction

NCT05878912

Heart Failure With Preserved Ejection Fraction Obesity

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Obesity and its related conditions are a significant cause of death and ill health. There have been a number of studies showing that weight loss, in particular that achieved by bariatric (weight-loss) surgery, results in improvement in obesity-related conditions such as type 2 diabetes mellitus. A large case-control study demonstrated a mean weight loss of 23.4% by 2 years and sustained mean weight loss of 16.1% compared to matched controls. 72% of patients with type 2 diabetes were in remission at 2 years and this was 36% at 10 years. Bariatric surgery also results in recovery from lipid disturbances with 62% of patients demonstrating normalisation of hypertriglyceridaemia (high fat levels in the blood) at 2 years and 46% at 10 years. There is also a smaller cohort of patients who, despite significant weight loss, do not experience remission of their obesity-related comorbidities.

The mechanisms for the improvement in obesity-related ill health are not well understood and little dedicated work has been undertaken on imaging in the obese population before and after treatment. For example, increased fat content in the liver, bone and pancreas is well described in obesity but it is unclear whether response to treatment is uniform across all these organs, or if there are specific patients who would benefit from additional or alternative interventions for hard to treat organ fat. The effect on remaining organ fat following treatment on clinical parameters such as body shape, and metabolism, is also unknown. Furthermore, it is not known if there are certain patterns of organ fat which may respond better to one type of therapy such as surgery compared to medical treatment for example, and choosing the best treatment for patients may be improved by a better understanding of organ fat. The effect of obesity on bone structure and strength, bone hormonal activity and metabolism is poorly understood. Finally, the link, if any, between patterns of organ fat and patients' genes, body shape and metabolism before and after treatment and is also unclear.

Treatment options for obesity continue to develop. Several novel medical (non-surgical) treatments for obesity have become available and the number of patients undergoing bariatric surgery continues to increase. There is therefore need to understand the mechanisms behind both weight loss (and the contribution of individual organs to this) and the improvement in obesity-related conditions. By gaining greater understanding of this, we aim to better predict outcomes for individual patients and better select the most appropriate treatment for them.

There has been recent research into MRI as a method of quantifying fat in abdominal organs such as the liver and pancreas. MRI has the advantages of being non-invasive (for example when compared to liver biopsy) and does not use ionising radiation unlike other imaging modalities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient Cohort 1

* Age 18 or over
* BMI greater than or equal to 30 (greater than or equal to 27.5 for patients of Asian origin)
* Due to undergo or referred for a formal treatment intervention for obesity (lifestyle modifications \[dietary change, behavioural therapy, increased physical activity\], surgical intervention or pharmacological treatment) as part of their usual clinical care
* Informed written consent
* Able to tolerate MRI

MRI

Intervention Type OTHER

MRI scan (not involving ionising radiation)

The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher

Written Consent

Intervention Type OTHER

Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.

Patient Cohort 2

* Age 18 or over
* Attending weight management service at UCLH
* Informed written consent
* Able to tolerate MRI

MRI

Intervention Type OTHER

MRI scan (not involving ionising radiation)

The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher

Written Consent

Intervention Type OTHER

Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.

Controls

* Age 18 or over
* BMI less than 25
* Informed written consent
* Able to tolerate MRI

MRI

Intervention Type OTHER

MRI scan (not involving ionising radiation)

The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher

Written Consent

Intervention Type OTHER

Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI

MRI scan (not involving ionising radiation)

The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher

Intervention Type OTHER

Written Consent

Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 or over
* BMI greater than or equal to 30
* Due to undergo or referred for a formal treatment intervention for obesity, as part of their usual clinical care.
* Informed consent

Cohort 2

* Age 18 or over
* Attending the weight management service at UCLH
* Informed consent

Controls

* Age 18 or over
* BMI less than 25
* Informed consent

Exclusion Criteria

* Absolute contraindication to MRI scan (e.g. metal foreign object)
* Unable to tolerate MRI scan (e.g. due to claustrophobia)
* MRI bore size inadequate to accommodate the patient
* Previous weight loss surgery (e.g. gastric band, gastric bypass, sleeve gastrectomy) \[Cohort 1 only\]
* Unable to give consent
* Pregnancy

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes